Zidovudine monotherapy in pregnancy: Is it state of the art?

HIV Medicine

Volumn 9, Issue 7, 2008, Pages 445-447

  Katzenstein, T L ^a   Gerstoft, J ^a  

^a International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

BIRTH WEIGHT; CESAREAN SECTION; CLINICAL TRIAL; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; GENE MUTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; INFANT DISEASE; MONOTHERAPY; PATIENT SELECTION; PRACTICE GUIDELINE; PREGNANCY; PREGNANT WOMAN; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SINGLE DRUG DOSE; TREATMENT DURATION; VERTICAL TRANSMISSION; VIRUS LOAD; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; FEMALE; HIV INFECTIONS; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; ZIDOVUDINE;

EID: 50149092455     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2008.00593.x     Document Type: Editorial

References (21)

1. Read P, Costelloe S, Mullen J et al. New mutations associated with resistance not detected following zidovudine monotherapy in pregnancy when used in accordance with British HIV Association guidelines. HIV Med 2008; 9, in press.
2. British HIV Association. Guidelines for the Management of HIV Infection in Pregnant Women and the Prevention of Mother-to-Child Transmission of HIV. Available online: http://www.bhiva.org/cms1191558.asp 2005.
3. British HIV Association. Management of HIV Infection in Pregnant Women. Available online: http://www.bhiva.org/cms1221368.asp 2007.
4. Jamieson DJ, Clark J, Kourtis AP et al. Recommendations for human immunodeficiency virus screening, prophylaxis, and treatment for pregnant women in the United States. Am J Obstet Gynecol 2007; 197 (Suppl. 3): 26-32.
5. Martin F, Taylor GP. Increased rates of preterm delivery are associated with the initiation of highly active antiretroviral therapy during pregnancy: A single-center cohort study. J Infect Dis 2007; 196: 558-561.
6. Thorne C, Patel D, Newell ML. Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe. AIDS 2004; 18: 2337-2339.
7. Cotter AM, Garcia AG, Duthely ML, Luke B, O'Sullivan MJ. Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or stillbirth? J Infect Dis 2006; 193: 1195-1201.
8. Grosch-Woerner I, Puch K, Maier RF et al. Increased rate of prematurity associated with antenatal antiretroviral therapy in a German/Austrian cohort of HIV-1-infected women. HIV Med 2008; 9: 6-13.
9. Tuomala RE, Shapiro DE, Mofenson LM et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med 2002; 346: 1863-1870.
10. Szyld EG, Warley EM, Freimanis L et al. Maternal antiretroviral drugs during pregnancy and infant low birth weight and preterm birth. AIDS 2006; 20: 2345-2353.
11. Beckerman KP. Protease inhibitor treatment of HIV-1-infected women may protect against extreme prematurity and very low birth weight. J Infect Dis 2008; 196: 1270-1271.
12. Kourtis AP, Schmid CH, Jamieson DJ, Lau J. Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: A meta-analysis. AIDS 2007; 21: 607-615.
13. Kully C, Yerly S, Erb P et al. Codon 215 mutations in human immunodeficiency virus-infected pregnant women. Swiss Collaborative 'HIV and Pregnancy' Study. J Infect Dis 1999; 179: 705-708.
14. Kuritzkes DR, Quinn JB, Benoit SL et al. Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) vs. zidovudine (ZDV) vs. ZDV plus 3TC in previously untreated patients. AIDS 1996; 10: 975-981.
15. Larder BA, Kohli A, Bloor S et al. Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2′,3′-dideoxyinosine or AZT plus 2′,3′-dideoxycytidine combination therapy. The Protocol 34,225-02 Collaborative Group. J Virol 1996; 70: 5922-5929.
16. Phillips AN, Staszewski S, Lampe F et al. Human immunodeficiency virus rebound after suppression to <400 copies/mL during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppression. J Infect Dis 2002; 186: 1086-1091.
17. Opravil M, Hirschel B, Lazzarin A et al. A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. J Infect Dis 2002; 185: 1251-1260.
18. Larbalestier N, Mullen J, O'Shea S et al. Drug resistance is uncommon in pregnant women with low viral loads taking zidovudine monotherapy to prevent perinatal HIV transmission. AIDS 2003; 17: 2665-2667.
19. Suy A, Hernandez S, Thorne C et al. Current guidelines on management of HIV-infected pregnant women: Impact on mode of delivery. Eur J Obstet Gynecol Reprod Biol 2008, doi: 10.1016/j.ejogrb.2007.12.007
20. Phillips A. Morbidity and mortality in the HAART era. 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 2008 [Abstract 8].
21. El-Sadr WM, Lundgren JD, Neaton JD et al. CD4 count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355: 2283-2296.